Decreased Kidney Graft Survival in Low Immunological Risk Patients Showing Inflammation in Normal Protocol Biopsies

Fernanda Ortiz, Rosana Gelpi, Ilkka Helanterä, Edoardo Melilli, Eero Honkanen, Oriol Bestard, Josep M Grinyo, Josep M Cruzado, Fernanda Ortiz, Rosana Gelpi, Ilkka Helanterä, Edoardo Melilli, Eero Honkanen, Oriol Bestard, Josep M Grinyo, Josep M Cruzado

Abstract

Introduction: The pros and cons for implementing protocol biopsies (PB) after kidney transplantation are still a matter of debate. We aimed to address the frequency of pathological findings in PB, to analyze their impact on long-term graft survival (GS) and to analyze the risk factors predicting an abnormal histology.

Methods: We analyzed 946 kidney PB obtained at a median time of 6.5 (±2.9) months after transplantation. Statistics included comparison between groups, Kaplan-Meier and multinomial logistic regression analysis.

Results and discussion: PB diagnosis were: 53.4% normal; 46% IFTA; 12.3% borderline and 4.9% had subclinical acute rejection (SCAR). Inflammation had the strongest negative impact on GS. Therefore we split the cases into: "normal without inflammation", "normal with inflammation", "IFTA without inflammation", "IFTA with inflammation" and "rejection" (including SCAR and borderline). 15-year GS in PB diagnosed normal with inflammation was significantly decreased in a similar fashion as in rejection cases. Among normal biopsies, inflammation increased significantly the risk of 15-y graft loss (P = 0.01). Variables that predicted an abnormal biopsy were proteinuria, previous AR and DR-mismatch.

Conclusion: We conclude that inflammation in normal PB is associated with a significantly lower 15-y GS, comparable to rejection or IFTA with inflammation.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Frequency of the lesions diagnosed…
Fig 1. Frequency of the lesions diagnosed in PB.
Fig 2. Impact of inflammation severity on…
Fig 2. Impact of inflammation severity on death censored graft survival.
Fig 3. Graft survival of Banff categories…
Fig 3. Graft survival of Banff categories split regarding the presence of inflammation.
In panel A: 15-y graft survival. In panel B: 15-y death-censored graft survival.

References

    1. Rush DN, Henry SF, Jeffery JR, Schroeder TJ, Gough J. Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation 1994. January;57(2):208–211.
    1. Rush D, Nickerson P, Gough J, McKenna R, Grimm P, Cheang M, et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998. November;9(11):2129–2134.
    1. Rush D, Arlen D, Boucher A, Busque S, Cockfield SM, Girardin C, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant 2007. November;7(11):2538–2545.
    1. Scholten EM, Rowshani AT, Cremers S, Bemelman FJ, Eikmans M, van Kan E, et al. Untreated rejection in 6-month protocol biopsies is not associated with fibrosis in serial biopsies or with loss of graft function. J Am Soc Nephrol 2006. September;17(9):2622–2632.
    1. Nankivell BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006. September;6(9):2006–2012.
    1. Legendre C, Canaud G, Martinez F. Factors influencing long-term outcome after kidney transplantation. Transplant Int 2014. January;27(1):19–27.
    1. Thierry A, Thervet E, Vuiblet V, Goujon JM, Machet MC, Noel LH, et al. Long-term impact of subclinical inflammation diagnosed by protocol biopsy one year after renal transplantation. Am J Transplant 2011. October;11(10):2153–2161. 10.1111/j.1600-6143.2011.03695.x
    1. Mengel M, Gwinner W, Schwarz A, Bajeski R, Franz I, Brocker V, et al. Infiltrates in protocol biopsies from renal allografts. Am J Transplant 2007. February;7(2):356–365.
    1. Rush DN, Gibson IW. The perils of immunosuppression minimization: lessons from protocol biopsies of renal allografts. Curr Op in Nephrol & Hypert 2015. November;24(6):582–586.
    1. Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012. May 9;307(18):1941–1951. 10.1001/jama.2012.3954
    1. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999. February;55(2):713–723.
    1. Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007. March;7(3):518–526.
    1. Mengel M, Sis B, Haas M, Colvin RB, Halloran PF, Racusen LC, et al. Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012. March;12(3):563–570. 10.1111/j.1600-6143.2011.03926.x
    1. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, et al. Antibody-mediated rejection criteria—an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003. June;3(6):708–714.
    1. Heilman RL, Devarapalli Y, Chakkera HA, Mekeel KL, Moss AA, Mulligan DC, et al. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. Am J Transplant 2010. March;10(3):563–570. 10.1111/j.1600-6143.2009.02966.x
    1. Mengel M, Chapman JR, Cosio FG, Cavaille-Coll MW, Haller H, Halloran PF, et al. Protocol biopsies in renal transplantation: insights into patient management and pathogenesis. Am J Transplant 2007. March;7(3):512–517.
    1. Mannon RB, Matas AJ, Grande J, Leduc R, Connett J, Kasiske B et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am J Transplant. 2010. September;10(9):2066–73 10.1111/j.1600-6143.2010.03240.x
    1. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005. October;5(10):2464–2472.
    1. Rush DN, Jeffery JR, Gough J. Sequential protocol biopsies in renal transplant patients: repeated inflammation is associated with impaired graft function at 1 year. Transplant Proc 1995. February;27(1):1017–1018.
    1. Seron D. Interstitial fibrosis and tubular atrophy in renal allograft protocol biopsies as a surrogate of graft survival. Transplant Proc 2009. March;41(2):769–770. 10.1016/j.transproceed.2008.12.027
    1. Gago M, Cornell LD, Kremers WK, Stegall MD, Cosio FG. Kidney allograft inflammation and fibrosis, causes and consequences. Am J Transplant 2012. May;12(5):1199–1207. 10.1111/j.1600-6143.2011.03911.x
    1. Kee TY, Chapman JR, O'Connell PJ, Fung CL, Allen RD, Kable K, et al. Treatment of subclinical rejection diagnosed by protocol biopsy of kidney transplants. Transplantation 2006. July 15;82(1):36–42.
    1. Moreso F, Carrera M, Goma M, Hueso M, Sellares J, Martorell J, et al. Early subclinical rejection as a risk factor for late chronic humoral rejection. Transplantation 2012. January 15;93(1):41–46. 10.1097/TP.0b013e31823bb647
    1. Roberts IS, Reddy S, Russell C, Davies DR, Friend PJ, Handa AI, et al. Subclinical rejection and borderline changes in early protocol biopsy specimens after renal transplantation. Transplantation 2004. April 27;77(8):1194–1198.
    1. Ponticelli C, Graziani G. Proteinuria after kidney transplantation. Transplant Int 2012. September;25(9):909–917.
    1. Jenni F, Riethmuller S, Wuthrich RP. Significance of urine diagnostic tests after renal transplantation. Kidney Blood Press Res 2013;37(2–3):116–123. 10.1159/000350065
    1. Oblak M, Kandus A, Mlinsek G, Buturovic-Ponikvar J, Arnol M. Increase in proteinuria after acute kidney graft rejection is associated with decreased graft function and survival. Transplant Proc 2013. May;45(4):1453–1457. 10.1016/j.transproceed.2013.02.106
    1. Shamseddin MK, Knoll GA. Posttransplantation proteinuria: an approach to diagnosis and management. Clin J Am Soc Nephrol 2011. July;6(7):1786–1793. 10.2215/CJN.01310211
    1. Halimi JM, Laouad I, Buchler M, Al-Najjar A, Chatelet V, Houssaini TS, et al. Early low-grade proteinuria: causes, short-term evolution and long-term consequences in renal transplantation. Am J Transplant 2005. September;5(9):2281–2288.
    1. Amer H, Fidler ME, Myslak M, Morales P, Kremers WK, Larson TS, et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 2007. December;7(12):2748–2756.
    1. Halimi JM, Matthias B, Al-Najjar A, Laouad I, Chatelet V, Marliere JF, et al. Respective predictive role of urinary albumin excretion and nonalbumin proteinuria on graft loss and death in renal transplant recipients. Am J Transplant 2007. December;7(12):2775–2781.
    1. Isoniemi H, Taskinen E, Hayry P. Histological chronic allograft damage index accurately predicts chronic renal allograft rejection. Transplantation 1994. December 15;58(11):1195–1198.
    1. Buchmann TN, Wolff T, Bachmann A, Guerke L, Steiger J, Mihatsch MJ, et al. Repeat true surveillance biopsies in kidney transplantation. Transplantation 2012. May 15;93(9):908–913. 10.1097/TP.0b013e318248cab0
    1. de Freitas DG, Sellares J, Mengel M, Chang J, Hidalgo LG, Famulski KS, et al. The nature of biopsies with "borderline rejection" and prospects for eliminating this category. Am J Transplant 2012. January;12(1):191–201. 10.1111/j.1600-6143.2011.03784.x

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj